Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase

Clinical and Experimental Allergy

Volumn 44, Issue 5, 2014, Pages 747-755

  Stoevesandt, J ^a   Hain, J ^b   Stolze, I ^a   Kerstan, A ^a   Trautmann, A ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

ACE inhibitor; Anaphylaxis; Beta blocker; Build up phase; Cardiovascular medication; Hymenoptera venom; Immunotherapy; Risk factor; Rush protocol; Safety

Indexed keywords

ALK LYOPHILISIERT SQ; ATENOLOL; BEE VENOM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYMENOPTERA VENOM; IMMUNOGLOBULIN E ANTIBODY; LISINOPRIL; METOPROLOL; QUINAPRIL; RAMIPRIL; TRYPTASE; UNCLASSIFIED DRUG; ALLERGEN; IMMUNOGLOBULIN E; VENOM;

ADULT; ANAPHYLAXIS; ARTICLE; DIAGNOSTIC PROCEDURE; DRUG DOSE INCREASE; DRUG SAFETY; ENVENOMATION; FEMALE; HUMAN; IMMUNOTHERAPY; INCIDENCE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN TEST; VENOM IMMUNOTHERAPY; VESPULA; AGED; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; DESENSITIZATION; DRUG INTERACTION; HYMENOPTERA; IMMUNOLOGY; MIDDLE AGED; RISK; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ALLERGENS; ANAPHYLAXIS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; DESENSITIZATION, IMMUNOLOGIC; DRUG INTERACTIONS; FEMALE; HUMANS; HYMENOPTERA; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VENOMS;

EID: 84903697001     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12276     Document Type: Article

References (43)

1. Boyle RJ, Elremeli M, Hockenhull J et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012; 10:CD008838.
2. Ruëff F, Przybilla B, Bilò MB et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010; 126:105-11.e5.
3. Mosbech H, Müller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:1005-10.
4. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study. III: Safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86:775-80.
5. Tunon-de-Lara JM, Villanueva P, Marcos M, Taytard A. ACE inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet 1992; 340:908.
6. Ober AI, MacLean JA, Hannaway PJ. Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J Allergy Clin Immunol 2003; 112:1008-9.
7. Wolf BL, Hamilton RG. Near-fatal anaphylaxis after Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1998; 102:527-8.
8. Borchers AT, Keen CL, Gershwin ME. Fatalities following allergen immunotherapy. Clin Rev Allergy Immunol 2004; 27:147-58.
9. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79:660-77.
10. Brehler R, Wolf H, Kütting B, Schnitker J, Luger T. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000; 105:1231-5.
11. González de Olano D, Alvarez-Twose I, Esteban-López MI et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008; 121:519-26.
12. Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64:1237-45.
13. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89:529-35.
14. Müller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005; 115:606-10.
15. White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol 2008; 101:426-30.
16. Lee S, Hess EP, Nestler DM et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol 2013; 131:1103-8.
17. Ruëff F, Przybilla B, Bilò MB et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047-54.
18. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
19. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154-235.
20. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273:1450-6.
21. Shekelle PG, Rich MW, Morton SC et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529-38.
22. Gibbons RJ, Abrams J, Chatterjee K et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41:159-68.
23. Saha SA, Molnar J, Arora RR. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials. J Cardiovasc Pharmacol Ther 2007; 12:192-204.
24. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49:S12-154.
25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-62.
26. Hermann K, Ring J. The renin-angiotensin system in patients with repeated anaphylactic reactions during hymenoptera venom hyposensitization and sting challenge. Int Arch Allergy Immunol 1997; 112:251-6.
27. Golden DB, Moffitt J, Nicklas RA et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011; 127:852-4.e1-23.
28. Krishna MT, Ewan PW, Diwakar L et al. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clin Exp Allergy 2011; 41:1201-20.
29. Bonifazi F, Jutel M, Bilò BM, Birnbaum J, Müller U. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-70.
30. Bilò BM, Ruëff F, Mosbech H, Bonifazi F, Oude-Elberink JN. Diagnosis of Hymenoptera venom allergy. Allergy 2005; 60:1339-49.
31. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010; 125:569-74, 574.e1-574.e7.
32. Muraro A, Roberts G, Clark A et al. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy 2007; 62:857-71.
33. Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol 2012; 130:698-704.
34. Blum S, Gunzinger A, Müller UR, Helbling A. Influence of total and specific IgE, serum tryptase, and age on severity of allergic reactions to Hymenoptera stings. Allergy 2010; 66:222-8.
35. Lockey RF, Turkeltaub PC, Baird-Warren IA et al. The Hymenoptera venom study I, 1979-1982: demographics and history-sting data. J Allergy Clin Immunol 1988; 82:370-81.
36. Simons FE. Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161-81.
37. Golden DB. Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol 2005; 115:439-47.
38. Golden DB, Marsh DG, Freidhoff LR et al. Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol 1997; 100:760-6.
39. Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993; 23:226-30.
40. Hepner MJ, Ownby DR, Anderson JA, Rowe MS, Sears-Ewald D, Brown EB. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections. J Allergy Clin Immunol 1990; 86:407-11.
41. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730-7.
42. Foody JM, Farrell MH, Krumholz HM. Beta-Blocker therapy in heart failure: scientific review. JAMA 2002; 287:883-9.
43. TenBrook JA Jr, Wolf MP, Hoffman SN et al. Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis. J Allergy Clin Immunol 2004; 113:977-82.